---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-25-000115"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:53:44.708246+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY

## Summary
- Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).
- Adjusted EBITDA $69.4M (34.2% margin); operating cash flow $49.6M.
- Pharma Manufacturer Solutions revenue +32% YoY; new pharmacy counter deals and ED subscription launched.
- Results in line with prior guidance; no explicit revision to outlook provided.

## SEC filing metadata
- accession: 0001809519-25-000115
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/0001809519-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/gdrx-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-25-000115
- JSON: https://secwatch.observer/filing/0001809519-25-000115.json
- Plain text: https://secwatch.observer/filing/0001809519-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.